A comparative study on the efficacy and safety of intravenous levetiracetam and phenobarbitone in the treatment of neonatal seizures

Deergha Bhasin; Anuj Sethi; Om Shankar Chaurasiya; Kawalpreet Chhabra

doi:10.18203/2349-3291.ijcp20250767

Authors

Deergha Bhasin Department of Pediatrics, Maharani Laxmi Bai Medical College Jhansi, Uttar Pradesh, India
Anuj Sethi Department of Pediatrics, Maharani Laxmi Bai Medical College Jhansi, Uttar Pradesh, India
Om Shankar Chaurasiya Department of Pediatrics, Maharani Laxmi Bai Medical College Jhansi, Uttar Pradesh, India
Kawalpreet Chhabra Department of Pediatrics, Maharani Laxmi Bai Medical College Jhansi, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20250767

Keywords:

Antiepileptic, Hammersmith infant neurological examination score, Levetiracetam, Neonatal seizure, Phenobarbitone

Abstract

Background: Seizures are the most common manifestation of neurological insult during the neonatal period with a significant risk of mortality and subsequent neurological disability. Phenobarbitone has been the mainstay of treatment for decades despite its limited efficacy and potential adverse effects. Levetiracetam being a newer antiepileptic with favourable pharmacological and clinical profile and better neurodevelopmental outcomes may be used as an alternative first line antiepileptic. This study compares the efficacy and safety of intravenous levetiracetam and phenobarbitone in the treatment of neonatal seizures.

Methods: Prospective randomized controlled trial conducted at level 3 Neonatal Intensive Care Unit including 150 neonates 0-28 days with clinical seizures randomized to receive either intravenous Levetiracetam or Phenobarbitone as first line antiepileptic. Cessation of seizures for 24 hours duration after drug administration is considered as primary outcome measure.

Results: Seizure control was noted in 53.3% neonates in phenobarbitone group, which was significantly higher as compared levetiracetam (21.3%, p<0.05) after first loading. A significantly higher percentage of neonates in levetiracetam group required further doses and another drug (25.3%). Adverse effects and requirement of mechanical ventilation was significantly higher in patients of phenobarbitone group (22.7%) (p<0.05). However neurological outcomes measured by HINE score did not show significant difference between the groups(p>0.05).

Conclusions: Phenobarbitone is found to be more efficacious than levetiracetam as a first line antiepileptic in terms of seizure control while levetiracetam requires more frequent dosing but with better safety profile and survival rates. Thus, levetiracetam can be considered as an alternative in treatment of neonatal seizures.

Metrics

Metrics Loading ...

References

Van LGM, Hellström-Westas L, Vries LS. Treatment of neonatal seizures. Seminars in Fetal and Neonatal Med. 2013;18(4):209-15. DOI: https://doi.org/10.1016/j.siny.2013.01.001

Glass HC, Kan J, Bonifacio SL, Ferriero DM. Neonatal seizures: treatment practices among term and preterm infants. Pediatr Neurol. 2012;46(2):111-5. DOI: https://doi.org/10.1016/j.pediatrneurol.2011.11.006

Volpe JJ. Neurology of the newborn. 5th ed. Philadelphia: Saunders Elsevier. 2008.

Emily S. Stieren, MD, PhD; Catherine A. Rottkamp, MD, PhD; Amy R. Brooks-Kayal, MD. Neonatal Seizures. Neoreviews. 2024;25(6):338–49. DOI: https://doi.org/10.1542/neo.25-6-e338

Manish Prasad,. Neonatal seizure: what is the cause?. BMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e6003 (Published 12 September 2012) Cite this as: BMJ 2012;345:e6003 DOI: https://doi.org/10.1136/bmj.e6003

Jogender Kumar, Jitendra Meena, Jaivinder Yadav, Lokesh Saini, Efficacy and Safety of Phenobarbitone as First-Line Treatment for Neonatal Seizure: A Systematic Review and Meta-Analysis, Journal of Tropical Pediatrics, Volume 67, Issue 1, February 2021, fmab008. DOI: https://doi.org/10.1093/tropej/fmab008

Qiao M-Y, Cui H-T, Zhao L-Z, Miao J-K and Chen Q-X (2021) Efficacy and Safety of Levetiracetam vs. Phenobarbital for Neonatal Seizures: A Systematic Review and Meta-Analysis. Front. Neurol. 12:747745. DOI: https://doi.org/10.3389/fneur.2021.747745

Kumar, J., Yadav, B., Meena, J. Levetiracetam versus Phenobarbitone for Management of Neonatal Seizures: A Systematic Review and Meta-analysis. Indian J Pediatr (2023). DOI: https://doi.org/10.1007/s12098-023-04905-1

Cynthia Sharpe. Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial. Pediatrics (2020) 145 (6): e20193182.

Evans D, Levene M. Neonatal seizuresArchives of Disease in Childhood - Fetal and Neonatal Edition 1998;78:F70-F75. DOI: https://doi.org/10.1136/fn.78.1.F70

Spagnoli, C., Pisani, F. Acute symptomatic seizures in newborns: a narrative review. Acta Epileptologica 6, 5 (2024). DOI: https://doi.org/10.1186/s42494-024-00151-w

Horn, A.R., Swingler, G.H., Myer, L. Early clinical signs in neonates with hypoxic ischemic encephalopathy predict an abnormal amplitude-integrated electroencephalogram at age 6 hours. BMC Pediatr 13, 52 (2013). DOI: https://doi.org/10.1186/1471-2431-13-52

Hay K, Nelin M, Carey H, Chorna O, Moore-Clingenpeel Ma Mas M, et al. NCH early developmental group hammersmith infant neurological examination asymmetry score distinguishes hemiplegic cerebral palsy from typical development. Pediatr Neurol. 2018;87:70-4. DOI: https://doi.org/10.1016/j.pediatrneurol.2018.07.002

Pervez AF. Randomized Controlled Trial between Levetiracetam and Phenobarbital in the Treatment of Neonatal Seizure due to Perinatal Asphyxia. Bangladesh J Child Health 2018;42(2):67-72. DOI: https://doi.org/10.3329/bjch.v42i2.37761

Prakash A, Richa R, Sahni GS. Neonatal seizures – Levetiracetam versus phenobarbital. Indian J Child Health. 2019;6(11):605-8. DOI: https://doi.org/10.32677/IJCH.2019.v06.i11.008